| Thomas Vanosdol, MD | |
|
24600 W 127th St Ste 225, Plainfield, IL 60585-9507 | |
| (630) 545-7833 | |
| (630) 545-7835 |
| Full Name | Thomas Vanosdol |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 25 Years |
| Location | 24600 W 127th St Ste 225, Plainfield, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275514366 | NPI | - | NPPES |
| P00726497 | Other | IL | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 036118974 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Edward Hospital | Naperville, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dupage Medical Group Ltd | 5496667941 | 1209 |
News Archive
New gastroenterology research carried out by the RCSI in conjunction with Trinity College Dublin and Johns Hopkins University in Baltimore, Maryland has uncovered a new route for the development of anti-diarrhoeal drugs.
ANI Pharmaceuticals, Inc., an emerging generic pharmaceutical company, today announced that it has acquired 31 previously marketed generic drug products from Teva Pharmaceuticals for $12.5 million in cash and a percentage of future gross profits from product sales.
A new collaboration covers the spectrum from molecules to therapies. Three research organisations have announced the merging of their expertise to fight cardiovascular diseases, which are among the most common health problems and causes of death in the world.
Scientific breakthroughs in molecular targeting, translational cancer research and cancer prevention will take center stage when more than 17,000 scientists from around the world gather at the Walter E. Washington Convention Center, April 17-21, for the AACR 101st Annual Meeting 2010.
› Verified 9 days ago
| Entity Name | Dupage Medical Group Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801833983 PECOS PAC ID: 5496667941 Enrollment ID: O20031110000535 |
News Archive
New gastroenterology research carried out by the RCSI in conjunction with Trinity College Dublin and Johns Hopkins University in Baltimore, Maryland has uncovered a new route for the development of anti-diarrhoeal drugs.
ANI Pharmaceuticals, Inc., an emerging generic pharmaceutical company, today announced that it has acquired 31 previously marketed generic drug products from Teva Pharmaceuticals for $12.5 million in cash and a percentage of future gross profits from product sales.
A new collaboration covers the spectrum from molecules to therapies. Three research organisations have announced the merging of their expertise to fight cardiovascular diseases, which are among the most common health problems and causes of death in the world.
Scientific breakthroughs in molecular targeting, translational cancer research and cancer prevention will take center stage when more than 17,000 scientists from around the world gather at the Walter E. Washington Convention Center, April 17-21, for the AACR 101st Annual Meeting 2010.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Vanosdol, MD Po Box 713260, Chicago, IL 60677-1260 Ph: (630) 469-9200 | Thomas Vanosdol, MD 24600 W 127th St Ste 225, Plainfield, IL 60585-9507 Ph: (630) 545-7833 |
News Archive
New gastroenterology research carried out by the RCSI in conjunction with Trinity College Dublin and Johns Hopkins University in Baltimore, Maryland has uncovered a new route for the development of anti-diarrhoeal drugs.
ANI Pharmaceuticals, Inc., an emerging generic pharmaceutical company, today announced that it has acquired 31 previously marketed generic drug products from Teva Pharmaceuticals for $12.5 million in cash and a percentage of future gross profits from product sales.
A new collaboration covers the spectrum from molecules to therapies. Three research organisations have announced the merging of their expertise to fight cardiovascular diseases, which are among the most common health problems and causes of death in the world.
Scientific breakthroughs in molecular targeting, translational cancer research and cancer prevention will take center stage when more than 17,000 scientists from around the world gather at the Walter E. Washington Convention Center, April 17-21, for the AACR 101st Annual Meeting 2010.
› Verified 9 days ago